Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula

ISME Journal

Volumn 9, Issue 3, 2015, Pages 552-562

  Xu, Jia ^a   Lian, Fengmei ^b   Zhao, Linhua ^b,c   Zhao, Yufeng ^c   Chen, Xinyan ^b   Zhang, Xu ^a   Guo, Yun ^b   Zhang, Chenhong ^a   Zhou, Qiang ^b   Xue, Zhengsheng ^a   Pang, Xiaoyan ^a   Zhao, Liping ^a,c   Tong, Xiaolin ^b  

^a Shanghai Jiao Tong University   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c Shanghai Jiao Tong University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES; GENE EXPRESSION; HEALTH RISK; HERB; IDENTIFICATION KEY; MEDICINE; METABOLISM; MICROBIOLOGY; SPECIES DIVERSITY;

CHINA;

FAECALIBACTERIUM; FAECALIBACTERIUM PRAUSNITZII;

GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HERBACEOUS AGENT;

ADULT; AGED; BACTERIUM; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GASTROINTESTINAL TRACT; GENETICS; GLUCOSE BLOOD LEVEL; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BACTERIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUGS, CHINESE HERBAL; FEMALE; GASTROINTESTINAL TRACT; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MICROBIOTA; MIDDLE AGED;

EID: 84923545804     PISSN: 17517362     EISSN: 17517370     Source Type: Journal    
DOI: 10.1038/ismej.2014.177     Document Type: Article

References (55)

1. Alberti KG, Zimmet PZ. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.
2. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG et al. (2011). Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 3: 559-572.
3. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A et al. (2004). The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101: 15718-15723.
4. Balamurugan R, Janardhan HP, George S, Chittaranjan SP, Ramakrishna BS. (2008). Bacterial succession in the colon during childhood and adolescence: molecular studies in a southern Indian village. Am J Clin Nutr 88: 1643-1647.
5. Bangsgaard Bendtsen KM, Krych L, Sorensen DB, Pang W, Nielsen DS, Josefsen K et al. (2012). Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. PLoS One 7: e46231.
6. Braak CT, Smilauer P. (2002). CANOCO Reference Manual and CanoDraw for Windows User's Guide: Software for Canonical Community Ordination (version 4.5). Microcomputer Power: Ithaca, New York.
7. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
8. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D et al. (2007a). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772.
9. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM et al. (2007b). Selective increases of bifidobacteria in gut microflora improve high-fatdiet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50: 2374-2383.
10. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM et al. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481.
11. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O et al. (2009). Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58: 1091-1103.
12. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK et al. (2010). QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7: 335-336.
13. Collins SM, Kassam Z, Bercik P. (2013). The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Curr Opin Microbiol 16: 240-245.
14. Davis LM, Martinez I, Walter J, Hutkins R. (2010). A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol 144: 285-292.
15. Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ. (2002). Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. Nov., comb. Nov. Int J Syst Evol Microbiol 52: 2141-2146.
16. Fei N, Zhao L. (2013). An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 7: 880-884.
17. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K et al. (2011). Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543-547.
18. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL et al. (2010). Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59: 3049-3057.
19. Gossling J, Moore WEC. (1975). Gemmiger formicilis, n. Gen., n. Sp., an anaerobic budding bacterium from intestines. Int J Syst Bacteriol 25: 202-207.
20. Hotamisligil GS. (2006). Inflammation and metabolic disorders. Nature 444: 860-867.
21. Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC, Cheng JT. (2003). Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. J Nat Prod 66: 788-792.
22. Khin Maung U, Myo K, Nyunt Nyunt W, Aye K, Tin U. (1985). Clinical trial of berberine in acute watery diarrhoea. BMJ (Clin Res Ed) 291: 1601-1605.
23. Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK et al. (2010). Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5: e9085.
24. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G et al. (2013). Richness of human gut microbiome correlates with metabolic markers. Nature 500: 541-546.
25. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H et al. (2008). Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 105: 2117-2122.
26. Liu IX, Durham DG, Richards RM. (2000). Baicalin synergy with beta-lactam antibiotics against methicillinresistant Staphylococcus aureus and other betalactam-resistant strains of S. aureus. J Pharm Pharmacol 52: 361-366.
27. Lozupone C, Knight R. (2005). UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol 71: 8228-8235.
28. Ludwig W, Strunk O, Westram R, Richter L, Meier H, Yadhukumar et al. (2004). ARB: a software environment for sequence data. Nucleic Acids Res 32: 1363-1371.
29. Luo CF, Yuan M, Chen MS, Liu SM, Zhu L, Huang BYet al. (2011). Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm 410: 138-144.
30. Park DY, Ahn YT, Park SH, Huh CS, Yoo SR, Yu R et al. (2013). Supplementation of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. PLoS One 8: e59470.
31. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F et al. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490: 55-60.
32. Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K. (1987). Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis 155: 979-984.
33. Rautio M, Saxen H, Siitonen A, Nikku R, Jousimies-Somer H. (2000). Bacteriology of histopathologically defined appendicitis in children. Pediatr Infect Dis J 19: 1078-1083.
34. Rautio M, Eerola E, Vaisanen-Tunkelrott ML, Molitoris D, Lawson P, Collins MD et al. (2003). Reclassification of Bacteroides putredinis (Weinberg et al., 1937) in a new genus Alistipes gen. Nov., as Alistipes putredinis comb. Nov., and description of Alistipes finegoldii sp. Nov., from human sources. Syst Appl Microbiol 26: 182-188.
35. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S et al. (2011). Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141: 1782-1791.
36. Shen J, Zhang B, Wei G, Pang X, Wei H, Li M et al. (2006). Molecular profiling of the Clostridium leptum subgroup in human fecal microflora by PCR-denaturing gradient gel electrophoresis and clone library analysis. Appl Environ Microbiol 72: 5232-5238.
37. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS et al. (2013). An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63: 727-735.
38. Shoelson SE. (2006). Inflammation and insulin resistance. J Clin Invest 116: 1793-1801.
39. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ et al. (2008). From the cover: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105: 16731-16736.
40. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. (2009). Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 126: 5-17.
41. Tian N, Wang J, Wang P, Song X, Yang M, Kong L. (2013). NMR-based metabonomic study of Chinese medicine Gegen Qinlian Decoction as an effective treatment for type 2 diabetes in rats. Metabolomics 9: 1228-1242.
42. Tong XL, Zhao HL, Lian FM, Zhou Q, Xia L, Zhang JC et al. (2011). Clinical observations on the dose-effect relationship of Gegen Qin Lian Decoction on 54 out-patients with type 2 diabetes. J Traditional Chinese Med 31: 56-59.
43. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. (2008). Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3: 213-223.
44. Waisundara VY, Hsu A, Tan BK, Huang D. (2009). Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats. Diabetes Metab Res Rev 25: 671-677.
45. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X et al. (2011). Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J 6: 320-329.
46. Whiting DR, Guariguata L, Weil C, Shaw J. (2011). IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321.
47. Xiao S, Fei N, Pang X, Shen J, Wang L, Zhang B et al. (2013). A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 87: 357-367.
48. Xu Y, Wang L, He J, Bi Y, Li M, Wang T et al. (2013). Prevalence and control of diabetes in Chinese adults. JAMA 310: 948-959.
49. Zhang C, Zhang M, Wang S, Han R, Cao Y, Hua W et al. (2009). Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J 4: 232-241.
50. Zhang C, Zhang M, Pang X, Zhao Y, Wang L, Zhao L. (2012a). Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J 6: 1848-1857.
51. Zhang CH, Xu GL, Liu YH, Rao Y, Yu RY, Zhang ZW et al. (2013). Anti-diabetic activities of Gegen Qinlian Decoction in high-fat diet combined with streptozotocininduced diabetic rats and in 3T3-L1 adipocytes. Phytomedicine 20: 221-229.
52. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C et al. (2012b). Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 7: e42529.
53. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N et al. (2008). Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93: 2559-2565.
54. Zhao L. (2013). The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol 11: 639-647.
55. Zhu XY, Su GY, Li ZH, Yue TL, Yan XZ, Wei HL. (1979). The metabolic fate of the effective components of puerariae. III. The metabolism of puerarin [article in Chinese]. Acta Pharm Sin 14: 349-355.